460 related articles for article (PubMed ID: 26444323)
1. Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.
Everett BM; Smith RJ; Hiatt WR
N Engl J Med; 2015 Oct; 373(17):1588-91. PubMed ID: 26444323
[No Abstract] [Full Text] [Related]
2. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.
Tice JA; Kazi DS; Pearson SD
JAMA Intern Med; 2016 Jan; 176(1):107-8. PubMed ID: 26662572
[No Abstract] [Full Text] [Related]
3. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
Joseph L; Robinson JG
Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
[TBL] [Abstract][Full Text] [Related]
4. [Inhibition of the protein PCSK9 is a promising target in the prevention of cardiovascular disease].
Christiansen MK; Jensen HK
Ugeskr Laeger; 2015 Mar; 177(11):. PubMed ID: 25786699
[TBL] [Abstract][Full Text] [Related]
5. [PCSK9 inhibitors: new treatment to lower cholesterol].
Gencer B; Rodondi N; Mach F
Rev Med Suisse; 2016 Mar; 12(508):440-2, 444. PubMed ID: 27089600
[TBL] [Abstract][Full Text] [Related]
6. Alirocumab (Praluent) to lower LDL-Cholesterol.
Med Lett Drugs Ther; 2015 Aug; 57(1475):113-5. PubMed ID: 26262881
[No Abstract] [Full Text] [Related]
7. [Lipid control in high-risk patients: focus on PCSK9 inhibitors].
Filardi PP; Paolillo S; Trimarco B
G Ital Cardiol (Rome); 2015 Jan; 16(1):44-51. PubMed ID: 25689751
[TBL] [Abstract][Full Text] [Related]
8. PCSK9 antibodies: A new class of lipid-lowering drugs.
Gouni-Berthold I
Atheroscler Suppl; 2015 May; 18():21-7. PubMed ID: 25936300
[TBL] [Abstract][Full Text] [Related]
9. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
10. PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?
Yang E
Clin Pharmacol Ther; 2015 Dec; 98(6):590-601. PubMed ID: 26369501
[TBL] [Abstract][Full Text] [Related]
11. PCSK9 inhibition: the next statin?
Vogel RA
J Am Coll Cardiol; 2012 Jun; 59(25):2354-5. PubMed ID: 22465426
[No Abstract] [Full Text] [Related]
12. PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia.
Paton DM
Drugs Today (Barc); 2016 Mar; 52(3):183-92. PubMed ID: 27186592
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular endocrinology in 2012: PCSK9-an exciting target for reducing LDL-cholesterol levels.
Betteridge DJ
Nat Rev Endocrinol; 2013 Feb; 9(2):76-8. PubMed ID: 23296165
[TBL] [Abstract][Full Text] [Related]
14. PCSK9 inhibitors--past, present and future.
Reiner Ž
Expert Opin Drug Metab Toxicol; 2015; 11(10):1517-21. PubMed ID: 26329686
[TBL] [Abstract][Full Text] [Related]
15. Evolocumab (AMG 145) for primary hypercholesterolemia.
Langslet G; Emery M; Wasserman SM
Expert Rev Cardiovasc Ther; 2015 May; 13(5):477-88. PubMed ID: 25824308
[TBL] [Abstract][Full Text] [Related]
16. [Risk of cardiovascular complications cut in half?].
Einecke D
MMW Fortschr Med; 2015 Apr; 157(6):26. PubMed ID: 26015190
[No Abstract] [Full Text] [Related]
17. PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a).
Ferdinand KC; Nasser SA
Cardiovasc Drugs Ther; 2015 Jun; 29(3):295-308. PubMed ID: 26068408
[TBL] [Abstract][Full Text] [Related]
18. [2nd PCSK9 inhibitor for effective LDL decrease].
Einecke D
MMW Fortschr Med; 2016 Feb; 158(2):65. PubMed ID: 26961048
[No Abstract] [Full Text] [Related]
19. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].
Avci A; Demir K; Altunkeser BB
Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 2():56-67. PubMed ID: 25693363
[TBL] [Abstract][Full Text] [Related]
20. How far down to push the LDL cholesterol? PCSK9 where statins fail.
Simko V; Ginter E
Bratisl Lek Listy; 2016; 117(4):193-4. PubMed ID: 27075380
[No Abstract] [Full Text] [Related]
[Next] [New Search]